Ramucirumab Cyramza 500 Injection

Q1: What is Ramucirumab (Cyramza) used for?

Ramucirumab treats advanced/metastatic gastric or GEJ adenocarcinoma after prior platinum/fluoropyrimidine chemotherapy, metastatic NSCLC after platinum chemotherapy (with docetaxel), metastatic colorectal cancer after bevacizumab-containing regimens (with FOLFIRI), and hepatocellular carcinoma with high AFP after sorafenib.

Q2: How does Ramucirumab work?

Ramucirumab is a fully human monoclonal antibody that specifically targets VEGFR-2 (vascular endothelial growth factor receptor 2). By blocking VEGF ligands from activating VEGFR-2, it prevents tumor angiogenesis — the formation of new blood vessels that feed the tumor.

Q3: How is Ramucirumab administered?

Ramucirumab is given as an intravenous infusion over approximately 60 minutes, typically every 2 weeks alone or with chemotherapy. Premedication with antihistamine before each infusion reduces infusion reaction risk.

Q4: What is the dosing schedule?

Standard dose is 8 mg/kg every 2 weeks for gastric, NSCLC, and CRC indications. For hepatocellular carcinoma: 8 mg/kg every 2 weeks. Dose reductions for toxicity are managed by the oncology team.

Q5: What are the most common side effects?

Common side effects include hypertension, diarrhea, headache, hyponatremia (low sodium), and proteinuria (protein in urine). Fatigue and peripheral edema also occur frequently.

Q6: What serious side effects require emergency care?

Seek immediate care for: sudden severe abdominal pain (GI perforation or fistula), stroke or heart attack symptoms (arterial thromboembolism), severe uncontrolled bleeding, severe infusion reactions (fever, chills, breathing difficulty), or signs of RPLS (headache, confusion, vision changes, seizures).

Q7: Why must Ramucirumab be held before surgery?

Like all anti-angiogenic agents, Ramucirumab impairs wound healing by inhibiting new blood vessel formation. It should be held for at least 28 days before elective surgery and not restarted until surgical wounds are completely healed.

Q8: What blood pressure monitoring is needed?

Blood pressure must be monitored before each Ramucirumab infusion. Hypertension requiring medication occurs in 15–25% of patients. Severe uncontrolled hypertension requires treatment interruption.

Q9: What drugs interact with Ramucirumab?

Formal drug interaction studies are limited, but all anti-angiogenic agents share class risks. Concurrent anticoagulants increase bleeding risk and require monitoring. Inform your oncologist of all medications, particularly blood thinners.

Q10: Is Ramucirumab safe during pregnancy?

No. Ramucirumab is expected to cause fetal harm based on its mechanism and animal studies. Contraception is required during treatment and for at least 3 months after the final dose. Breastfeeding should be avoided during and after treatment.

Q11: How should Ramucirumab vials be stored?

Store at 2°C–8°C. Do not freeze or shake. Protect from light. Keep in the original carton until use. Once diluted for infusion, use within 24 hours.

Q12: Is Ramucirumab available without a prescription?

No. Ramucirumab is a specialist prescription-only biological therapy administered only in hospital oncology settings under oncologist supervision.